📣 VC round data is live. Check it out!
- Public Comps
- ImExHS
ImExHS Valuation Multiples
Discover revenue and EBITDA valuation multiples for ImExHS and similar public comparables like Welby, Physitrack, NextPlat, MedApp and more.
ImExHS Overview
About ImExHS
ImExHS Ltd is engaged in the development and sale of its Hiruko software platform. The software consists of Radiology, Cardiology, Pathology information systems, and Picture Archiving and Communications Systems. The segments of the company are Software and Radiology Services. The company derives maximum revenue from Radiology segment.
Founded
2001
HQ

Employees
400
Website
Financials (LTM)
EV
$12M
Valuation Multiples
Start free trialImExHS Financials
ImExHS reported last 12-month revenue of $21M and EBITDA of $1M.
In the same LTM period, ImExHS generated $1M in EBITDA and had net loss of ($934K).
ImExHS P&L
In the most recent fiscal year, ImExHS reported revenue of $21M and EBITDA of $1M.
ImExHS is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of 6%, and net margin of (10%).
Financial data powered by Morningstar, Inc.
ImExHS Stock Performance
ImExHS has current market cap of $14M, and enterprise value of $12M.
ImExHS's stock price is $0.26.
ImExHS has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12M | $14M | -0.0% | — | — | — | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImExHS Valuation Multiples
ImExHS trades at 0.6x EV/Revenue multiple, and 8.7x EV/EBITDA.
ImExHS Financial Valuation Multiples
As of May 23, 2026, ImExHS has market cap of $14M and EV of $12M.
ImExHS has a P/E ratio of (14.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ImExHS Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ImExHS Margins & Growth Rates
ImExHS grew revenue by 12% and EBITDA by 46% in the last fiscal year.
In the most recent fiscal year, ImExHS reported gross margin of 100%, EBITDA margin of 6%, and net margin of (10%).
ImExHS Margins
ImExHS Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
ImExHS Operational KPIs
ImExHS's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
ImExHS's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ImExHS's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
ImExHS Competitors
ImExHS competitors include Welby, Physitrack, NextPlat, MedApp, NRGene, CurveBeam AI, Vidavo, Media Lab, MRSO and VSee Health.
Most ImExHS public comparables operate across Healthcare Software, HealthTech, B2B SaaS and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.2x | 3.2x | (4.2x) | — | |||
| 0.9x | 1.1x | (7.4x) | 28.5x | |||
| 0.1x | — | (0.8x) | — | |||
| 16.0x | — | 65.0x | — | |||
| 1.7x | — | (5.5x) | — | |||
| 3.1x | 3.4x | (3.7x) | (3.7x) | |||
| 7.8x | — | 1135.3x | — | |||
| 4.1x | — | 13.3x | — | |||
This data is available for Pro users. Sign up to see all ImExHS competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ImExHS
| When was ImExHS founded? | ImExHS was founded in 2001. |
| Where is ImExHS headquartered? | ImExHS is headquartered in Australia. |
| How many employees does ImExHS have? | As of today, ImExHS has over 400 employees. |
| Is ImExHS publicly listed? | Yes, ImExHS is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of ImExHS? | ImExHS trades under IME ticker. |
| When did ImExHS go public? | ImExHS went public in 2005. |
| Who are competitors of ImExHS? | ImExHS main competitors include Welby, Physitrack, NextPlat, MedApp, NRGene, CurveBeam AI, Vidavo, Media Lab, MRSO, VSee Health. |
| What is the current market cap of ImExHS? | ImExHS's current market cap is $14M. |
| What is the current revenue of ImExHS? | ImExHS's last 12 months revenue is $21M. |
| What is the current revenue growth of ImExHS? | ImExHS revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of ImExHS? | Current revenue multiple of ImExHS is 0.6x. |
| Is ImExHS profitable? | Yes, ImExHS is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ImExHS? | ImExHS's last 12 months EBITDA is $1M. |
| What is ImExHS's EBITDA margin? | ImExHS's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of ImExHS? | Current EBITDA multiple of ImExHS is 8.7x. |
| What is the current FCF of ImExHS? | ImExHS's last 12 months FCF is $2M. |
| What is ImExHS's FCF margin? | ImExHS's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of ImExHS? | Current FCF multiple of ImExHS is 7.7x. |
| How many companies ImExHS has acquired to date? | ImExHS hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies ImExHS has invested to date? | ImExHS hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to ImExHS
Lists including ImExHS
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.